Roche posts rise in profit in 2010

Swiss pharmaceutical group Roche has reported a four per cent increase in full-year net profit to SFr8.89 billion ($9.52 billion) in 2010.

This content was published on February 2, 2011 and agencies

Growth in sales of Roche's anti-cancer drugs was unable to compensate for a drop in sales of the group’s Tamiflu treatment and the surge in the Swiss franc. Full-year sales fell by three per cent to SFr47.47 billion, according to figures published on Wednesday.

Commenting on the Basel-based group’s performance, CEO Severin Schwan said the results were “solid despite an increasingly challenging market environment”.

Roche said it expects healthcare reforms in the United States and European austerity measures to dampen growth in 2011.

The group is hoping to save SFr1.8 billion in 2011 through a restructuring plan announced in November.

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Weekly top stories

Keep up to date with the best stories from SWI on a range of topics, straight into your mailbox.


The SBC Privacy Policy provides additional information on how your data is processed.